Advice
following an abbreviated submission:
ledipasvir/sofosbuvir (Harvoni®) is accepted for restricted use within NHSScotland.
Indication under review: treatment of chronic hepatitis C (CHC) in adolescents aged 12 to <18 years.
SMC restriction: genotype 1 and 4 CHC only.
SMC has previously accepted ledipasvir/sofosbuvir for use in adults with genotype 1 and 4 CHC.
Download detailed advice45KB (PDF)
Medicine details
- Medicine name:
- ledispavir / sofosbuvir (Harvoni)
- SMC ID:
- 1343/18
- Indication:
- Treatment of chronic hepatitis C infection in adolescents aged 12 to < 18 years
- Pharmaceutical company
- Gilead Sciences Ltd
- BNF chapter
- Infections
- Submission type
- Abbreviated submission
- Status
- Restricted
- Date advice published:
- 11 June 2018